Takeda Lifts Full-Year Forecasts and Launches New PID Therapy, But Investor Debate on Valuation Intensifies
Takeda Pharmaceutical raises its FY2025 revenue and profit guidance following resilient nine-month results and announces U.S. availability of a new ready-to-use immunoglobulin therapy for primary immunodeficiency, fueling discussions on its growth strategy amid high debt and margin pressures.